ZYBERNO
Stock Report
Updated Aug 31, 2026

LIFECORE BIOMEDICAL, INC. (LFCR)

Healthcare • NASDAQ

$4.54

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
LIFECORE BIOMEDICAL, INC. (LFCR) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-0.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LIFECORE BIOMEDICAL, INC. (LFCR) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.54
Market Cap:$170.59M

Valuation Multiples (2)

P/S Ratio:2.26x
Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$309.39M
Ev Ebitda Ratio:38.74x
Pfcf Ratio:49.73x

Price Action & Momentum (1)

% of 52-Week High:50.6%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:10.6%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-195.7%
Latest Earnings Filed:2025-04-03

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-13.6%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):-8.4%
Operating Cash Flow Growth Rate (Linear):26.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.87x
Quick Ratio:2.69x
Cash Ratio:0.80x

Leverage Analysis (1)

Debt To Ebitda:19.54x

Coverage Ratios (2)

Interest Coverage Ratio:-0.09x
Times Interest Earned:-0.09

Capital Structure (4)

Working Capital:62,050,000.00
Cash And Cash Equivalents:17,241,000.00
Long Term Debt:$155.07M
Net Debt:$138.80M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $75.52M
Linear Growth: -13.6%
📊 Click to view full LFCR Revenue analysis & methodology →
Cost Of Revenue Ttm:$51.83M

Profitability Breakdown (2)

Gross profit TTM: $23.69M
Linear Growth: 2.6%
📊 Click to view full LFCR Gross Profit analysis & methodology →
-$733.00K

Bottom Line Performance (3)

-$17.96M
Income Before Tax:-$38.69M
Ebitda Ttm:7,987,000.00

Operating Expenses (5)

Operating Expenses:57,926,000.00
R And D Expense:7,719,000.00
Sga Expense:35,345,000.00
Income Tax Expense:$410.00K
Interest Expense:7,751,000.00

Expense Ratios (3)

R And D To Revenue Percentage:22.6%
Sga To Revenue Percentage:103.4%
Ebitda Margin:10.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$229.50M
Current Assets:$83.69M
Ppe Net:123,714,000.00
Goodwill:13,881,000.00
Intangible Assets:$4.20M

Liability Structure (4)

Total Liabilities:263,594,000.00
Current Liabilities:21,641,000.00
Long Term Debt:$155.07M
Short Term Debt:$970.00K

Equity & Capital (3)

Equity:-$34.09M
Retained Earnings:-$244.34M
Common Stock:75,000,000.00

Working Capital Items (3)

Accounts Receivable:30,303,000.00
Inventory:25,475,000.00
Accounts Payable:7,534,000.00

Special Items (2)

Contract Liabilities:5,279,000.00
Stock Based Compensation:2,085,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $7.33M
Linear Growth: 26.9%
Free cash flow TTM: $3.63M
Linear Growth: -8.4%
📊 Click to view full LFCR Free Cash Flow analysis & methodology →

Investment Activities (1)

Investing Cash Flow:-$1.12M

Financing Activities (3)

Financing Cash Flow:-$256.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:8,720,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.48

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.01
Operating Cash Flow Per Share:$0.20

Book Value & Capital (2)

Book Value Per Share:-$0.91
Cash Per Share:0.46

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.33x
Working Capital Turnover Ttm:1.22x

Receivables Management (2)

Receivables Turnover Ttm:2.49x
Days Sales Outstanding Ttm:146.46

Inventory Management (2)

Inventory Turnover Ttm:2.03x
Days Inventory Outstanding Ttm:179.39

Payables & Cash Cycle (2)

Days Payable Outstanding:53.05
Cash Conversion Cycle:272.80
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-13.6%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):-8.4%
Operating Cash Flow Growth Rate (Linear):26.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):2.6%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:LFCR
Company Name:LIFECORE BIOMEDICAL, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:37.57M
Shares Outstanding Basic:37.57M
Shares Outstanding Diluted:37.57M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 07:35:36 UTC
Data Timestamp:2026-08-18T20:04:05.870597
Scroll to Top